US 12458662 B1Patent grantUnited States

g-C3N4 Nanohybrid for Cancer-Cell Screening

Official patent title

Anticancer agents comprising a g-C3N4@CuO/MgAl2O4 nanohybrid

Arabic title: عوامل مضادة للسرطان تشتمل على هجين نانوي من g-C3N4@CuO/MgAl2O4

Invention

Problem

Cancer treatment can be limited by non-specific toxicity, low bioavailability, resistance, and dose requirements, while nanomaterials introduce additional concerns about selectivity, clearance, biosafety, and scalable manufacture.

Why it matters

In-vitro inhibition of cultured cancer cells can identify a research lead, but it does not demonstrate normal-cell selectivity, animal efficacy, biodistribution, human safety, dosing, or clinical benefit.

Approach

The method contacts HepG-2 or MCF-7 cells with a porous g-C3N4@CuO/MgAl2O4 nanohybrid and measures cell-growth inhibition and IC50 values.

Who may benefit

Potential beneficiaries include cancer-nanomedicine researchers, cell-biology laboratories, materials-toxicology teams, oncology discovery groups, and translational centers evaluating inorganic nanomaterials.

Potential value

The disclosure connects a compositionally and structurally defined three-phase nanohybrid with reported IC50 ranges in two named cancer-cell lines and a corresponding thermal synthesis method.

Background

Chemotherapy can be constrained by systemic toxicity, resistance, solubility, bioavailability, and poor targeting. Nanomaterials are investigated as active agents or delivery platforms because size, shape, and surface can be engineered, but they also raise concerns about biocompatibility, clearance, accumulation, reproducible manufacture, and translation. The patent evaluates a carbon-nitride/copper-oxide/magnesium-aluminate hybrid against HepG-2 and MCF-7 cell lines. These cell-culture data are preliminary and cannot establish a safe or effective treatment in animals or people.

Technology overview

The hybrid contains 2–18 wt.% g-C3N4, 1–10 wt.% CuO, and 75–95 wt.% MgAl2O4. Claims report an IC50 of 50–70 μg/mL for HepG-2 and 100–120 μg/mL for MCF-7 cells. CuO and MgAl2O4 particles of 2–10 nm are dispersed on g-C3N4 nanosheets, with defined BET and pore ranges. Synthesis mixes magnesium, aluminum, and copper salts with fuel, calcines at 600–800 °C for 2–4 hours, then heats the product with urea at 550–650 °C for 20–60 minutes.

Potential applications

Potential in-vitro research with HepG-2 liver-cancer cells.
Potential in-vitro research with MCF-7 breast-cancer cells.
Potential nanomaterial cytotoxicity and mechanism studies.
Potential preclinical lead evaluation after normal-cell selectivity testing.

Evidence-supported advantages

Defines all three component weight ranges.
Reports IC50 ranges for two named cell lines.
Specifies nanosheet, particle, surface-area, and pore characteristics.
Provides a corresponding material-synthesis route.

Development stage

Patent publication describing material synthesis, characterization, and in-vitro cancer-cell assays; independent validation, animal or clinical efficacy, safety, and commercialization were not established.

Commercial opportunity

The material may support early-stage cancer-nanomedicine research licensing. Translation requires independent replication, normal-cell selectivity, mechanism and uptake studies, biodistribution, clearance and accumulation, dose and route definition, formulation, sterility, immunotoxicity and genotoxicity, animal efficacy, comprehensive toxicology, reproducible medical-grade manufacture, and regulated clinical trials before therapeutic use.

Patent classifications

WIPO IPC

A61K33/08Preparations for medical, dental or toiletry purposes
A61K33/34Preparations for medical, dental or toiletry purposes

CPC

A61K33/08Preparations for medical, dental or toiletry purposes
A61K33/44Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations
A61K33/34Preparations for medical, dental or toiletry purposes

Inventors

First inventorBabiker Yagoub Elhadi Abdulkhair
InventorMohamed Khairy Abdel Fattah Omran

Keywords

g-C3N4
CuO
MgAl2O4
nanohybrid
HepG-2
MCF-7
IC50
in-vitro cancer research

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.